These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 25597593)
21. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739 [TBL] [Abstract][Full Text] [Related]
23. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase. Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760 [TBL] [Abstract][Full Text] [Related]
24. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010 [TBL] [Abstract][Full Text] [Related]
25. Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I. Martin PK; Stilhano RS; Samoto VY; Takiya CM; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; Marques FL; Otake AH; Chammas R; Han SW PLoS One; 2014; 9(3):e92420. PubMed ID: 24642723 [TBL] [Abstract][Full Text] [Related]
26. In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors. Di Natale P; Di Domenico C; Villani GR; Lombardo A; Follenzi A; Naldini L Eur J Biochem; 2002 Jun; 269(11):2764-71. PubMed ID: 12047386 [TBL] [Abstract][Full Text] [Related]
27. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893 [TBL] [Abstract][Full Text] [Related]
28. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Ponder KP; Wang B; Wang P; Ma X; Herati R; Wang B; Cullen K; O'Donnell P; Ellinwood NM; Traas A; Primeau TM; Haskins ME Mol Ther; 2006 Jul; 14(1):5-13. PubMed ID: 16698321 [TBL] [Abstract][Full Text] [Related]
29. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model. Fraga M; Bruxel F; Diel D; de Carvalho TG; Perez CA; Magalhães-Paniago R; Malachias Â; Oliveira MC; Matte U; Teixeira HF J Control Release; 2015 Jul; 209():37-46. PubMed ID: 25886705 [TBL] [Abstract][Full Text] [Related]
30. alpha-L-Iduronidase transport in neurites. Chen F; Vitry S; Hocquemiller M; Desmaris N; Ausseil J; Heard JM Mol Genet Metab; 2006 Apr; 87(4):349-58. PubMed ID: 16439176 [TBL] [Abstract][Full Text] [Related]
31. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Ou L; Przybilla MJ; Koniar B; Whitley CB Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892 [TBL] [Abstract][Full Text] [Related]
32. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts. Huang MM; Wong A; Yu X; Kakkis E; Kohn DB Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437 [TBL] [Abstract][Full Text] [Related]
33. Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. Boado RJ; Pardridge WM Mol Pharm; 2017 Apr; 14(4):1271-1277. PubMed ID: 28279069 [TBL] [Abstract][Full Text] [Related]
34. Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I. Miyadera K; Conatser L; Llanga TA; Carlin K; O'Donnell P; Bagel J; Song L; Kurtzberg J; Samulski RJ; Gilger B; Hirsch ML Mol Ther; 2020 Jun; 28(6):1455-1463. PubMed ID: 32330426 [TBL] [Abstract][Full Text] [Related]
35. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883 [TBL] [Abstract][Full Text] [Related]
36. Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I). Barbosa Mendes A; do Nascimento CC; D'Almeida V PLoS One; 2019; 14(12):e0220429. PubMed ID: 31834922 [TBL] [Abstract][Full Text] [Related]
38. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987 [TBL] [Abstract][Full Text] [Related]
39. Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I. Hubel A; Stroncek D; Pan D; Whitley CB; McCullough J J Hematother; 1998 Dec; 7(6):505-14. PubMed ID: 9919944 [TBL] [Abstract][Full Text] [Related]
40. Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome. Dai M; Han J; El-Amouri SS; Brady RO; Pan D Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2680-5. PubMed ID: 24550296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]